Jerini AG was a

pharmaceutical company The pharmaceutical industry discovers, develops, produces, and markets drugs or pharmaceutical drugs for use as medications to be administered to patients (or self-administered), with the aim to cure them, vaccinate them, or alleviate sympt ...

based in

Berlin Berlin is Capital of Germany, the capital and largest city of Germany, both by area and List of cities in Germany by population, by population. Its more than 3.85 million inhabitants make it the European Union's List of cities in the European U ...

, Germany, which focused on the discovery and development of novel

peptide Peptides (, ) are short chains of amino acids linked by peptide bonds. Long chains of amino acids are called proteins. Chains of fewer than twenty amino acids are called oligopeptides, and include dipeptides, tripeptides, and tetrapeptides. ...

-based drugs. Using a proprietary technology platform, Peptides-to-Drugs (P2D), Jerini pursued disease indications for which limited, inadequate, or no treatment options exist. As a result, Jerini established a drug pipeline composed of its own programs as well as others in collaboration with partners. Jerini's commercialization strategy was to market new drugs in niche indications independently and in larger indications with partners. Jerini was acquired by Shire plc in 2008. Jerini started operations in 1994. Jerini's subsidiaries Jerini US Inc. and JPT Peptide Technologies GmbH, provider of

peptides Peptides (, ) are short chains of amino acids linked by peptide bonds. Long chains of amino acids are called proteins. Chains of fewer than twenty amino acids are called oligopeptides, and include dipeptides, tripeptides, and tetrapeptides. ...

and peptide microarrays, were acquired by Theracode GmbH, Mainz in 2009. Jerini was financed with

venture capital Venture capital (often abbreviated as VC) is a form of private equity financing that is provided by venture capital firms or funds to start-up company, startups, early-stage, and emerging companies that have been deemed to have high growth poten ...

provided by TVM and HealthCap. It went public on the Prime Standard of the Frankfurt Stock Exchange (JI4), and had raised a total of over 130 million Euro in public and private financing to date.

Firazyr (icatibant)

Jerini's lead compound

Firazyr Icatibant, sold under the brand name Firazyr, is a medication for the symptomatic treatment of acute attacks of hereditary angioedema (HAE) in adults with C1-esterase-inhibitor deficiency. It is not effective in angioedema caused by medication f ...

(icatibant), is an inhibitor of the action of the hormone

bradykinin Bradykinin (BK) (Greek brady-, slow; -kinin, kīn(eîn) to move) is a peptide that promotes inflammation. It causes arterioles to dilate (enlarge) via the release of prostacyclin, nitric oxide, and endothelium-derived hyperpolarizing factor and m ...

on its B2 receptor. This compound was in-licensed from Aventis in 2001. It has been approved for hereditary angioedema in all member states of the European Union in July 2008. The drug was granted FDA approval on August 25, 2011.

Peptides-to-Drugs (P2D) platform

Based on its P2D platform, Jerini established several in-house development programs, to address indications within the

ophthalmology Ophthalmology ( ) is a surgical subspecialty within medicine that deals with the diagnosis and treatment of eye disorders. An ophthalmologist is a physician who undergoes subspecialty training in medical and surgical eye care. Following a med ...

oncology Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of cancer. A medical professional who practices oncology is an ''oncologist''. The name's etymological origin is the Greek word ὄγκος (''ó ...

, and inflammatory therapeutic areas. The most advanced of these programs targeted age-related macular degeneration (AMD), the leading cause of vision loss and blindness in people over the age of 55 in developed countries. Jerini's compound (JSM 6427) has shown significant efficacy in combating disease progression in preclinical models. Jerini's proprietary Peptides-to-Drugs (P2D) technology was used to identify peptide drug lead structures and systematically transform them into peptidomimetic (injectable) and small-molecule (oral) drugs, depending on the indication. This enabled Jerini to develop novel drug candidates for diseases that were difficult to access using traditional drug discovery methods. The ability to produce both peptidomimetics and small molecule drugs as drug candidates has enabled the simultaneous development of drugs for acute and chronic treatments against the same target molecule (target).

References

{{Reflist

External links

Official website

JPT Peptide Technologies

European HAE information portal
Pharmaceutical companies disestablished in 2008 Manufacturing companies based in Berlin Pharmaceutical companies of Germany Pharmaceutical companies established in 1994 Medical and health organisations based in Berlin 2008 mergers and acquisitions